RNAC earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -1.40. Updated 2026-07-23.
Cartesian Therapeutics (RNAC) Research Hub
Cartesian Therapeutics (RNAC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 8.19 USD (-5.75%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.40, market cap 0.24B. This hub links to the full technical, earnings and options research available for RNAC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 8.19 USD (-5.75%) |
| 52-week range | 7.27 USD – 11 USD |
| Trend regime | Range |
| 14-day RSI | 43.9 (Bearish) |
| Trailing P/E | -1.40 |
| Market cap | 0.24B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for RNAC
Covered Call on RNAC: how it works, illustrative setup around the real 8.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RNAC: how it works, illustrative setup around the real 8.19 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RNAC: how it works, illustrative setup around the real 8.19 USD price, max profit/loss, breakeven and when to use it. Educational.
RNAC technical analysis: range, last 8.19 USD, RSI 43.9, 52w range 7.27 USD–11 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is RNAC in?
Cartesian Therapeutics (RNAC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RNAC in an uptrend or downtrend?
As of 2026-09-11, RNAC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RNAC's trailing P/E ratio?
RNAC's trailing P/E is -1.40, with a market cap of 0.24B. See the earnings research page for full valuation detail.
When does RNAC next report earnings?
RNAC is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.83 USD.